Laurus Labs Q1 FY27: CDMO Growth Accelerates, Revenue Crosses ₹2,000 Crore, Management Raises Capex for Future Expansion

What Happened ?

Management stated that Laurus Labs is benefiting from strong global demand for integrated pharmaceutical manufacturing and complex technology platforms.

The company continues shifting from a predominantly generic pharmaceutical business toward a higher-margin CDMO-led business model while simultaneously investing in future technologies such as:

• Peptides
• Antibody Drug Conjugates (ADCs)
• Gene Therapy
• Advanced Biologics
• Precision Fermentation

According to management, these investments are expected to support growth over the next decade rather than only the next few quarters.

key details

CDMO Continues to Become the Largest Growth Driver:

The biggest highlight of Q1 FY27 was the exceptional performance of the CDMO business.

Key highlights include:

• CDMO revenue grew 69% YoY.
• Commercial manufacturing contributed approximately 55% of CDMO revenue.
• Remaining revenue primarily came from Phase III and late-stage clinical projects expected to transition into commercial manufacturing.
• Growth was driven by increasing commercial supplies for multiple global pharmaceutical companies.

Management highlighted that no single customer or product dominates the CDMO business, reducing concentration risk and improving long-term sustainability.

Commercial Pipeline Continues Expanding:

Laurus indicated that multiple late-stage projects are progressing toward commercial production.

Management explained that:

• Several Phase III molecules are nearing commercial launch.
• Recently approved products are beginning commercial supply.
• Existing customers continue expanding manufacturing requirements.
• New multinational pharmaceutical companies are being onboarded.

The company believes commercial manufacturing will continue increasing as more clinical-stage products receive regulatory approvals.

Capex Raised Again to Meet Customer Demand:

One of the most important discussions during the earnings call was Laurus Labs’ revised capital expenditure plan.

Management confirmed FY27 capex guidance has increased to ₹2,000 crore.

The additional investment will support:

• API manufacturing expansion.
• CDMO capacity.
• Human Health programmes.
• Animal Health projects.
• Peptide manufacturing.
• Advanced intermediates.
• New technology platforms.

Management clarified that the higher investment is driven by confirmed customer demand rather than speculative expansion. Capacity is being built for multiple customers and products, not a single project. 

Future Growth Technologies Receive Significant Investment:

Laurus continues investing aggressively in emerging pharmaceutical modalities.

Major focus areas include:

• Antibody Drug Conjugates (ADCs)
• Gene Therapy
• Cell Therapy
• Peptides
• Precision Fermentation
• Advanced Biologics

The company signed a development and commercial agreement with Aarvik Therapeutics covering two ADC molecules for the Indian market and expects these programmes to progress through clinical development over the coming years.

Peptides Expected to Become a Meaningful Business:

Management confirmed that peptide manufacturing is becoming an increasingly important strategic area.

Although it declined to discuss customer-specific programmes, Laurus stated that:

• Commercial-scale peptide capacity is progressing.
• The opportunity extends well beyond GLP-1 obesity drugs.
• Multiple therapeutic categories are under development.
• Future growth is expected across several peptide classes.

Management believes peptides will become an important contributor over the medium term. 

Affordable Medicines Continue Delivering Stable Growth:

The Affordable Medicines division maintained healthy momentum.

Highlights include:

• Revenue increased 10% YoY to ₹1,156 crore.
• Continued leadership in ARV and oncology APIs.
• Strong demand for recently launched products in developed markets.
• New commercial office established in South Africa.
• Product registrations expanded across emerging markets.
• Cumulative DMF filings increased to 92.
• Developed market formulation filings reached 96. 

Laurus Bio Building the Next Growth Platform:

Although Laurus Bio currently contributes a relatively small share of revenue, management views it as a major long-term opportunity.

Current developments include:

• Revenue grew 21% YoY.
• Commercial fermentation facility construction remains on schedule.
• First phase of over 400 KL capacity expected to become operational by year-end.
• Business expanding across:
  • Animal-origin-free media
  • Industrial enzymes
  • Precision fermentation
  • CDMO biologics

Management expects the next 18–24 months to determine the long-term scale of this business. 

Long-Term Vision: Integrated Pharmaceutical Company:

Management reiterated its ambition of becoming a fully integrated pharmaceutical partner.

The long-term strategy includes offering customers:

• Starting materials
• Advanced intermediates
• APIs
• Drug products
• Commercial manufacturing
• End-to-end CDMO services

The company expects CDMO to contribute at least 50% of total revenue by FY30, reflecting a major shift in Laurus’ business mix toward higher-value manufacturing.

Strong Quality and ESG Performance:

Operational execution remained strong during the quarter.

Highlights include:

• Successfully completed 24 customer and regulatory audits.
• No critical observations reported.
• Science Based Targets initiative (SBTi) validated Laurus’ near-term emissions reduction targets.
• Continued investments in renewable energy and sustainability initiatives.

Risk Analysis

Summary:

• While Laurus is entering a strong growth phase, investors should monitor execution of its large capital expenditure programme and commercial conversion of late-stage CDMO projects.

Key Risks:

• Delays in customer product approvals.
• Slower conversion of Phase III projects into commercial manufacturing.
• Large capital expenditure execution.
• Regulatory risks across global markets.
• Commercialisation timelines for biologics and peptides.
• Working capital requirements.

Worst Case:

• If commercial launches are delayed or utilisation of new facilities takes longer than expected, return ratios could remain below management’s long-term targets despite higher investments.

Risk Level: Medium

Company Commentary

• Founder and CEO Dr. Satyanarayana Chava stated that Laurus Labs is witnessing strong demand for specialised technology platforms and integrated manufacturing capabilities.
• The company remains committed to investing in future growth areas such as CDMO, peptides, ADCs, gene therapy and biologics while expanding manufacturing capacity to meet customer demand.
• Management believes these investments will create sustainable long-term value and position Laurus as a fully integrated pharmaceutical company.